ArticleCureus2026
The ScinTwelve Study: Pharmacoscintigraphic Evaluation and Pharmacokinetic Assessment of a Vitamin B12 Sustained-Release Tablet in Healthy Human Subjects.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral bioavailability of vitamin B12 is highly dependent on gastrointestinal transit and site-specific release, with optimal absorption occurring in the terminal ileum. Sustained-release formulations were designed to enhance targeted delivery and prolong systemic exposure.
objectiveThis study aimed to evaluate the in vivo disintegration pattern, gastric emptying, and gastrointestinal transit of a vitamin B12 sustained-release tablet using pharmacoscintigraphy and to correlate these findings with systemic bioavailability.
methodsAn open-label, single-dose pharmacoscintigraphy study was conducted in six healthy adult male subjects. The investigational product (vitamin B12 1500 mcg sustained-release tablet) was radiolabeled with technetium-99m (
resultsThe upper placebo layer disintegrated rapidly in the stomach within 1.0 ± 0.0 minutes, with gastric emptying completed by 0.7 ± 0.2 hours. The lower sustained-release layer remained intact in the stomach and emptied at 120.00 ± 0.00 hours, followed by gradual intestinal disintegration between four and six hours. Colonic arrival occurred at 336.00 ± 53.67 hours. Serum vitamin B12 levels peaked at eight hours (296.00 ± 94.65 pg/mL), indicating delayed absorption corresponding to intestinal release. Sustained levels were maintained up to 48 hours, and no adverse events were reported.
conclusionThe vitamin B12 sustained-release tablet exhibited effective biphasic release with targeted intestinal delivery and sustained bioavailability, confirming its design intent and potential for improved therapeutic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.